Oppenheimer & CO Inc Bio Atla, Inc. Transaction History
Oppenheimer & CO Inc
- $5.91 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding BCAB
# of Institutions
88Shares Held
24.8MCall Options Held
140KPut Options Held
4.6K-
Soleus Capital Management, L.P. Greenwich, CT4.07MShares$5.57 Million1.14% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$3.81 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.1MShares$2.88 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$2.62 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.47MShares$2.02 Million0.62% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $49.7M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...